<!DOCTYPE html>
<html lang="en">

<head>
	<meta charset="UTF-8" />
	<meta name="viewport" content="width=device-width, initial-scale=1.0, shrink-to-fit=no" />
	<link rel="preconnect" href="https://fonts.gstatic.com">
	<link href="https://fonts.googleapis.com/css2?family=Rubik:ital,wght@0,300;0,400;1,700&display=swap" rel="stylesheet">
	<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css"
		integrity="sha512-+4zCK9k+qNFUR5X+cKL9EIR+ZOhtIloNl9GIKS57V1MyNsYpYcUrUeQc9vNfzsWfV28IaLL3i96P9sdNyeRssA=="
		crossorigin="anonymous" />
	<link rel="stylesheet" href="./bootstrap/bootstrap.min.css" />
	<link rel="stylesheet" href="./css/main.css" />
	<link rel="icon" type="image/png" href="./img/icons/favicon-32x32.png" />
	<title>Joanna Miklosz Scientist</title>
</head>

<body>
	<header>
		<nav class="navbar fixed-top navbar-expand-md bg-light navbar-light nav__bor">
			<a href="/" class="navbar-brand">
				<img src="./img/asia/android-chrome-192x192.png" class="m-0 hero__img" />
			</a>
			<button class="navbar-toggler" type="button" data-target="#nav" data-toggle="collapse" aria-controls="#nav"
				aria-expanded="false" aria-label="toggle navigation">
				<span class="navbar-toggler-icon"></span>
			</button>
			<div class="navbar-collapse collapse collapse-on-click" id="nav">
				<ul class="nav navbar-nav bd-navbar-nav mr-auto">
					<li class="nav-item">
						<a class="nav-link active mr-lg-3 ml-3" href="#hero"><span class="sr-only">current</span>Start</a>
					</li>
					<li class="nav-item">
						<a class="nav-link mr-lg-3 ml-3" href="#publications">Publications </a>
					</li>
					<li class="nav-item">
						<a class="nav-link mr-lg-3 ml-3" href="#projects">Projects</a>
					</li>
					<li class="nav-item">
						<a class="nav-link mr-lg-3 ml-3" href="#contact">Contact</a>
					</li>
				</ul>
				<div class="row float-right">
					<a href="https://orcid.org/0000-0003-0958-0454" target="_blank" rel="noopener noreferrer"
						class="col-3 col-lg-3 text-center">
						<img src="https://img.icons8.com/windows/64/000000/orcid.png" class="nav__socialIcon" /> </a>
					<a href="https://www.researchgate.net/profile/Joanna_Miklosz " target="_blank" rel="noopener noreferrer"
						class="col-3 col-lg-3 text-center">
						<img src="https://img.icons8.com/windows/64/000000/researchgate.png" class="nav__socialIcon" /> </a>
					<a href="https://scholar.google.pl/citations?user=xamzqDYAAAAJ&hl=pl" target="_blank"
						rel="noopener noreferrer" class="col-3 col-lg-3 text-center"><img
							src="https://img.icons8.com/ios/50/000000/google-scholar--v2.png" class="nav__socialIcon" /></a>
					<a href="https://www.linkedin.com/in/joanna-mik%C5%82osz-402540162/?originalSubdomain=pl" target="_blank"
						rel="noopener noreferrer" class="col-3 col-lg-3 text-center"><img
							src="https://img.icons8.com/ios/50/000000/linkedin.png" class="nav__socialIcon" /></a>
				</div>

			</div>
		</nav>
	</header>
	<main>
		<section id="hero" class="hero">
			<div class="container ml-xl-5">
				<div class="hero__text col-12 col-xl-10 nav__bor">
					<div class="col-12">
						<h1 class="hero__header">Joanna Mikłosz (Zajaczkowska),<br /> <small>PhD Pharm</small></h1>
						<p class="hero__paragraph">
							Hi! I am a research scientist and PhD candidate at Medical University in Bialystok, Poland. I finish my
							PhD
							this year.
							My main area of interest is coagulation disorders and finding new medicament for treating complications
							after use of
							heparin. Please get familiar with my publications. I am open for post-doc studies. See you at the
							conferences!
						</p>
						<br />
						<a href="#contact" class="btn btn-warning btn-md nav__bor" role="button"><span
								class="hero__buttonText">Contact
								me: </span><svg width="1em" height="1em" viewBox="0 0 16 16" class="bi bi-arrow-down"
								fill="currentColor" xmlns="http://www.w3.org/2000/svg">
								<path fill-rule="evenodd"
									d="M8 1a.5.5 0 0 1 .5.5v11.793l3.146-3.147a.5.5 0 0 1 .708.708l-4 4a.5.5 0 0 1-.708 0l-4-4a.5.5 0 0 1 .708-.708L7.5 13.293V1.5A.5.5 0 0 1 8 1z" />
							</svg> </i></a>
						<button type="submit" onclick="window.open('./cv_pdf/JoannaMiklosz.pdf')" download
							class="btn btn-outline-warning hero__buttonText">download
							resume</>
					</div>

				</div>
			</div>
			</div>
			</div>
			</div>
		</section>

		<section id="publications" class="container-fluid publications text-center">
			<div>
				<h2 class="text-light">My publications:</h2>
				<p class="lead text-light">
					Please get familiar with my scientific publications, presented in
					chronological oder:
				</p>
				<div class="row d-flex justify-content-around">
					<div class="col-12 col-lg-10 text-center">
						<div class="card-group">
							<div class="accordion" id="accordionPublications">
								<div class="row">
									<div class="card col-12 col-lg-6 col-xl-4 bg-light mb-3 border border-dark">
										<div class="card-block">
											<img src="./img/papers/j_pharmacol_exp.JPG"
												alt="heparin-binding copolymer as a complete antidote for low molecular weight heparin in rats publication"
												class="mb-3" />
											<h6 class="card-subtitle text-muted d-none d-lg-block">Abstract</h6>
											<button class="btn btn-outline-warning d-lg-none" type="button" data-toggle="collapse"
												data-target="#j_pharmacol_exp" aria-expanded="true" aria-controls="j_pharmacol_exp">
												See Abstract
											</button>
										</div>
										<div class="card-block collapse abstract" id="j_pharmacol_exp" aria-labelledby="j_pharmacol_exp"
											data-parent="#accordionPublications">
											<p class="card-text abstract__text">
												Bleeding resulting from the application of low-molecular-weight heparins (LMWHs) may be treated
												with protamine sulfate,
												but this treatment lacks efficiency; its action against antifactor Xa activity is limited to
												∼60%. Moreover, protamine
												sulfate can cause life-threatening hypersensitivity reactions. We developed diblock
												heparin-binding copolymer (HBC),
												which can neutralize the anticoagulant activity of parenteral anticoagulants. In the present
												study, we explored the
												safety profile of HBC and its potential to reverse enoxaparin, nadroparin, dalteparin, and
												tinzaparin in human plasma
												and at in vivo conditions. HBC-LMWH complexes were characterized using zeta potential,
												isothermal titration calorimetry,
												and dynamic light scattering. The rat cardiomyocytes and human endothelial cells were used for
												the assessment of in
												vitro toxicity. Male Wistar rats were observed for up to 4 days after HBC administration for
												clinical evaluation, gross
												necropsy, and biochemistry and histopathological analysis. Rats were treated with LMWHs alone or
												followed by short-time
												intravenous infusion of HBC, and bleeding time and antifactor Xa activity were measured. HBC
												completely reversed
												antifactor Xa activity prolonged in vitro by all LMWHs with an optimal weight ratio of 2.5:1.
												The complexes of HBC-LMWHs
												were below 5 µm. We observed no effects on the viability of cardiovascular cells treated with
												HBC at concentrations up
												to 0.05 mg/ml. Single doses up to 20 mg/kg of HBC were well tolerated by rats. HBC completely
												reversed the effects of
												LMWHs on bleeding time and antifactor Xa activity in vivo after 20 minutes and retained ∼80% and
												∼60% of reversal
												activity after 1 and 2 hours, respectively. Well-documented efficacy and safety of HBC both in
												vitro and in vivo make
												this polymer a promising candidate for LMWHs reversal. SIGNIFICANCE STATEMENT: Over the last
												decade, there has been
												significant progress in developing antidotes for the reversal of anticoagulants. Until now,
												there has been no effective
												and safe treatment for patients with severe bleeding under low-molecular-weight heparin therapy.
												Based on our in vitro
												and in vivo studies, heparin-binding copolymer seems to be a promising candidate for
												neutralizing all clinically
												relevant low-molecular-weight heparins.
											</p>
											<a type="button" class="btn btn-outline-success" target="_blank" rel="noopener noreferrer"
												href="https://pubmed.ncbi.nlm.nih.gov/27223896/">
												Learn more
											</a>
										</div>
									</div>
									<div class="card col-12 col-lg-6 col-xl-4 bg-light mb-3 border border-dark">
										<div class="card-block">
											<img src="./img/papers/rsc_advances.JPG"
												alt="neutralization of heparin sulfate by heparin-binding copolymer as a potential therapeutic target publication"
												class="mb-md-3" />
											<h6 class="card-subtitle text-muted d-none d-lg-block">Abstract</h6>
											<button class="btn btn-outline-warning d-lg-none" type="button" data-toggle="collapse"
												data-target="#rsc_advances" aria-expanded="true" aria-controls="rsc_advances">
												See Abstract
											</button>
										</div>
										<div class="card-block collapse abstract" id="rsc_advances" aria-labelledby="rsc_advances"
											data-parent="#accordionPublications">
											<p class="card-text abstract__text">
												Besides regulating ligand–receptor and cell–cell interactions, heparan sulfate (HS) may
												participate in the development
												of many diseases, such as cancer, bacterial or viral infections, and their complications, like
												bleeding or inflammation.
												In these cases, the neutralization of HS could be a potential therapeutic target. The
												heparin-binding copolymer (HBC,
												PEG41-PMAPTAC53) was previously reported by us as a fully synthetic compound for efficient and
												safe neutralization of
												heparins and synthetic anticoagulants. In a search for molecular antagonists of HS, we examined
												the activity of HBC as
												an HS inhibitor both in vitro and in vivo and characterized HBC/HS complexes. Using a
												colorimetric Azure A method,
												isothermal titration calorimetry and dynamic light scattering techniques we found that HBC binds
												HS by forming complexes
												below 200 nm with less than 1 : 1 stoichiometry. We confirmed the HBC inhibitory effect in rats
												by measuring activated
												partial thromboplastin time, prothrombin time, anti-factor Xa activity, anti-factor IIa
												activity, and platelet
												aggregation. HBC reversed the enhancement of all tested parameters caused by HS demonstrating
												that cationic synthetic
												block copolymers may have a therapeutic value in various disorders involving overproduction of
												HS.
											</p>
											<a type="button" class="btn btn-outline-success" target="_blank" rel="noopener noreferrer"
												href="https://pubs.rsc.org/en/content/articlelanding/2019/ra/c8ra09724k#!divAbstract">
												Learn more
											</a>
										</div>
									</div>
									<div class="card col-12 col-lg-6 col-xl-4 bg-light mb-3 border border-dark">
										<div class="card-block">
											<h6 class="card-title">Marine Drugs: 2019, IF: 30</h6>
											<img src="./img/papers/marine_protamine.JPG"
												alt="inhibitory effect of protamine is attenuated by heparin without inducing thrombocytopenia in rodents publication"
												class="mb-3" />
											<h6 class="card-subtitle text-muted d-none d-lg-block">Abstract</h6>
											<button class="btn btn-outline-warning d-lg-none" type="button" data-toggle="collapse"
												data-target="#marineProtamine" aria-expanded="true" aria-controls="marineProtamine">
												See Abstract
											</button>
										</div>
										<div class="card-block collapse abstract" id="marineProtamine" aria-labelledby="marineProtamine"
											data-parent="#accordionPublications">
											<p class="card-text abstract__text">
												Protamine sulfate (PS) is a polycationic protein drug obtained from the sperm of fish, and is
												used
												to reverse the
												anticoagulant effect of unfractionated heparin (UFH). However, the interactions between PS, UFH,
												and
												platelets are still
												not clear. We measured the platelet numbers and collagen-induced aggregation, P-selectin,
												platelet
												factor 4,
												β-thromboglobulin, prostacyclin metabolite, D-dimers, activated partial thromboplastin time,
												prothrombin time,
												anti-factor Xa, fibrinogen, thrombus weight and megakaryocytopoiesis in blood collected from
												mice
												and rats in different
												time points.. All of the groups were treated intravenously with vehicle, UFH, PS, or UFH with
												PS.
												We
												found a short-term
												antiplatelet activity of PS in mice and rats, and long-term platelet-independent antithrombotic
												activity in rats with
												electrically-induced thrombosis. The antiplatelet and antithrombotic potential of PS may
												contribute
												to bleeding risk in
												PS-overdosed patients. The inhibitory effect of PS on the platelets was attenuated by UFH
												without
												inducing
												thrombocytopenia. Treatment with UFH and PS did not affect the formation, number, or activation
												of
												platelets, or the
												thrombosis development in rodents.
											</p>
											<a type="button" class="btn btn-outline-success"
												href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780366/pdf/marinedrugs-17-00539.pdf"
												target="_blank" rel="noopener noreferrer">
												Learn more
											</a>
										</div>
									</div>
									<div class="card col-12 col-lg-6 col-xl-4 bg-light rounded mb-3 border border-dark">
										<div class="card-block">
											<img src="./img/papers/macromolecules.JPG"
												alt="anticoagulant properties of polysodium-2-acrylamido-2-methylpropanesulfonate-based di and triblock polymers publication"
												class="mb-3" />
											<h6 class="card-subtitle text-muted d-none d-lg-block">Abstract</h6>
											<button class="btn btn-outline-warning d-lg-none" type="button" data-toggle="collapse"
												data-target="#macromolecules" aria-expanded="false" aria-controls="macromolecules">
												See Abstract
											</button>
										</div>
										<div class="card-block collapse abstract" id="macromolecules" aria-labelledby="macromolecules"
											data-parent="#accordionPublications">
											<p class=" card-text show abstract__text">
												Di- and triblock copolymers with low dispersity of molecular weight were synthesized using
												radical
												addition–fragmentation chain transfer polymerization. The copolymers contained anionic
												poly(sodium
												2-acrylamido-2-methylpropanesulfonate) (PAMPS) block as an anticoagulant component. The block
												added
												to lower the
												toxicity was either poly(ethylene glycol) (PEG) or poly(2-(methacryloyloxy)ethyl
												phosphorylcholine)
												(PMPC). The polymers
												prolonged clotting times both in vitro and in vivo. The influence of the polymer architecture
												and
												composition on the
												efficacy of anticoagulation and safety parameters was evaluated. The polymer with the optimal
												safety/efficacy profile
												was PEG47-b-PAMPS108, i.e., a block copolymer with the degrees of polymerization of PEG and
												PAMPS
												blocks equal to 47 and
												108, respectively. The anticoagulant action of copolymers is probably mediated by antithrombin,
												but
												it differs from that
												of unfractionated heparin. PEG47-b-PAMPS108 also inhibited platelet aggregation in vitro and
												increased the prostacyclin
												production but had no antiplatelet properties in vivo. PEG47-b-PAMPS108 anticoagulant activity
												can
												be efficiently
												reversed with a copolymer of PEG and poly((3-(methacryloylamino)propyl)trimethylammonium
												chloride)
												(PMAPTAC)
												(PEG41-b-PMAPTAC53, HBC), which may be attributed to the formation of polyelectrolyte complexes
												with
												PEG shells without
												anticoagulant properties.
											</p>
											<a type="button" class="btn btn-outline-success" target="_blank" rel="noopener noreferrer"
												href="https://pubs.acs.org/doi/pdf/10.1021/acs.biomac.8b00691">
												Learn more
											</a>
										</div>
									</div>
									<div class="card col-12 col-lg-6 col-xl-4 bg-light mb-3 border border-dark">
										<div class="card-block">
											<img src="./img/papers/JPP.JPG" alt="pharmacogenetic considerations of anticoagulant medication"
												class="mb-3" />
											<h6 class="card-subtitle text-muted d-none d-lg-block">Abstract</h6>
											<button class="btn btn-outline-warning d-lg-none" type="button" data-toggle="collapse"
												data-target="#jpp" aria-expanded="true" aria-controls="jpp">
												See Abstract
											</button>
										</div>
										<div class="card-block collapse abstract" id="jpp" aria-labelledby="jpp"
											data-parent="#accordionPublications">
											<p class="card-text abstract__text">
												Predicting the clinical consequences of anticoagulant therapy by identifying gene variants could
												help in the risk
												assessment of thrombosis or bleeding before and after surgery and may result in choosing more
												beneficial therapy. This
												work provides an overview of pharmacogenetic data of commonly used anticoagulant medication. The
												review focuses on
												polymorphisms influencing the efficacy and safety of the parenteral and oral anticoagulants.
												There is evidence that
												heparin resistance and heparin-induced thrombocytopenia could be genetically determined but it
												does not mean that the
												risk of bleeding or thromboembolism is related to mutations in general. CYP2C9 and VKORC1
												polymorphisms are essential
												determinants in the genotype-guided dosing of warfarin and may distinguish patients who would
												benefit from switching to
												direct oral anticoagulants (DOACs). Further multi-ethnic studies associating genes of enzymes
												metabolizing DOACs with
												primary clinical endpoints are necessary. Pharmacogenetics-based dosing of anticoagulant
												medication should point towards
												the subpopulation of patients.
											</p>
											<a type="button" class="btn btn-outline-success" target="_blank" rel="noopener noreferrer"
												href="https://pubmed.ncbi.nlm.nih.gov/30415235/">
												Learn more
											</a>
										</div>
									</div>
									<div class="card col-12 col-lg-6 col-xl-4 bg-light mb-3 border border-dark">
										<div class="card-block">
											<img src="./img/papers/blacki_i_cienie.JPG"
												alt="blacki i cienie farmakoterapii antykoagulacyjnej publications" class="mb-3" />
											<h6 class="card-subtitle text-muted d-none d-lg-block">Abstract</h6>
											<button class="btn btn-outline-warning d-lg-none" type="button" data-toggle="collapse"
												data-target="#cienie" aria-expanded="true" aria-controls="cienie">
												See Abstract
											</button>
										</div>
										<div class="card-block collapse abstract" id="cienie" aria-labelledby="cienie"
											data-parent="#accordionPublications">
											<p class="card-text abstract__text">
												Antithrombotic drugs are the mainstay of treatment and prevention of thromboembolic disease. The
												principal risk of
												antithrombotic therapy is a severe bleeding that requires an appropriate medical intervention.
												The overall strategy of
												managing a major bleeding in patients receiving anticoagulants includes the cessation of
												therapy, as well as an attempt
												to reverse any remaining antithrombotic effects using, if available, specific antidotes or
												general procoagulants. In the
												present review, we discuss the most commonly used anticoagulants, including their mechanisms of
												action,
												pharmacokinetics, and side effects, as well as general guidelines for management of major
												bleeding in patients treated
												with these drugs. In addition, we describe approaches, currently at the preclinical and clinical
												study stage, with the
												potential to improve the safety of anticoagulant therapy in the future. We present an example of
												the contribution of
												pharmacists to an increased efficacy and safety of anticoagulant treatments.
											</p>
											<a type="button" class="btn btn-outline-success" target="_blank" rel="noopener noreferrer"
												href="http://biuletynfarmacji.wum.edu.pl/1610Kalaska/Kalaska.pdf">
												Learn more
											</a>
										</div>
									</div>
									<div class="card col-12 col-lg-6 col-xl-4 bg-light mb-3 border border-dark">
										<div class="card-block">
											<img src="./img/papers/maloplytkowosc.JPG"
												alt="protamine-induced thrombocytopenia a new clinical complication or other type of heparin-induced thrombocytopenia publication"
												class="mb-3" />
											<h6 class="card-subtitle text-muted d-none d-lg-block">Abstract</h6>
											<button class="btn btn-outline-warning d-lg-none" type="button" data-toggle="collapse"
												data-target="#maloplytkowosc" aria-expanded="true" aria-controls="maloplytkowosc">
												See Abstract
											</button>
										</div>
										<div class="card-block collapse abstract" id="maloplytkowosc" aria-labelledby="maloplytkowosc"
											data-parent="#accordionPublications">
											<p class="card-text abstract__text">
												Protamine is widely used to neutralize the anticoagulant effects of unfractionated heparin,
												particularly after cardiac
												surgery. Recent reports suggest that some patients undergoing cardiopulmonary bypass exposed to
												heparin and protamine
												may develop thrombocytopenia. Multimolecular protamine-heparin complexes lead to immunization
												and production of
												immunoglobulin G class antibodies that may activate platelets through FcγIIa receptors. Some
												patients injected with
												protamine during cardiopulmonary bypass have increased the risk of early thromboembolic events
												due to the presence of
												these antibodies in the blood. In the present review, we will focus on studies investigating the
												mechanism of platelet
												activation by anti-protamine-heparin antibodies. We will compare antibodies that are associated
												with immune
												heparin-induced thrombocytopenia. In addition, we will describe the clinical consequences of
												protamine-induced
												thrombocytopenia, risk factors and general guidelines for management of thromboembolic
												complications in the post-cardiac
												surgery patients.
											</p>
											<a type="button" class="btn btn-outline-success" target="_blank" rel="noopener noreferrer"
												href="https://journals.viamedica.pl/folia_cardiologica/article/view/FC.2017.0068/44073">
												Learn more
											</a>
										</div>
									</div>
									<div class="card col-12 col-lg-6 col-xl-4 bg-light mb-3 border border-dark">
										<div class="card-block">
											<img src="./img/papers/expert_opinion.JPG"
												alt="tocicology of heparin reversal with protamine: past, present and future publication"
												class="mb-3" />
											<h6 class="card-subtitle text-muted d-none d-lg-block">Abstract</h6>
											<button class="btn btn-outline-warning d-lg-none" type="button" data-toggle="collapse"
												data-target="#expertOpinion" aria-expanded="true" aria-controls="expertOpinion">
												See Abstract
											</button>
										</div>
										<div class="card-block collapse abstract" id="expertOpinion" aria-labelledby="expertOpinion"
											data-parent="#accordionPublications">
											<p class="card-text abstract__text">
												Introduction: Unfractionated heparin is a strongly anionic anticoagulant used extensively in
												medicine to prevent blood
												clotting. In the case of an emergency bleeding in response to heparin, the protamine sulfate is
												administered. Despite
												its extensive clinical use, protamine may produce life-threatening side effects such as systemic
												hypotension,
												catastrophic pulmonary vasoconstriction or allergic reactions. Recent studies have demonstrated
												new
												organ-specific
												complications of the heparin reversal with protamine.

												Areas covered: Past and present knowledge of the mechanisms responsible for the toxicity of
												protamine and the most
												promising potential replacements of protamine in the different phases of development.

												Expert opinion: Despite of the low therapeutic index, protamine is the only registered antidote
												of
												heparins. The
												toxicology of protamine depends on a complex interaction of the high molecular weight, a
												cationic
												peptide with the
												surfaces of the vasculature and blood cells. The mechanisms involve membrane receptors and ion
												channels targeted by
												different vasoactive compounds, such as nitric oxide, bradykinin or histamine. Unacceptable side
												effects of protamine
												have led to a search for new alternatives: UHRA, LMWP, and Dex40-GTMAC3 are in the preclinical
												stage; the two other
												agents (andexanet alfa and PER977) are already in the advanced clinical phases.
											</p>
											<a type="button" class="btn btn-outline-success" target="_blank" rel="noopener noreferrer"
												href="https://pubmed.ncbi.nlm.nih.gov/27223896/">
												Learn more
											</a>
										</div>
									</div>
									<div
										class="card col-12 col-lg-6 col-xl-4 bg-light rounded ml-lg-auto mr-lg-auto mb-3 border border-dark">
										<div class="card-block">
											<img src="./img/papers/trans_res.JPG"
												alt="heparin-binding copolymer reverse effects of unfractionated heparin, enoxaparin, and fondaparinux in rats and mice publication"
												class="mb-3" />
											<h6 class="card-subtitle text-muted d-none d-lg-block">Abstract</h6>
											<button class="btn btn-outline-warning d-lg-none" type="button" data-toggle="collapse"
												data-target="#transRes" aria-expanded="false" aria-controls="transRes">
												See Abstract
											</button>
										</div>
										<div class="card-block collapse abstract" id="transRes" aria-labelledby="transRes"
											data-parent="#accordionPublications">
											<p class=" card-text abstract__text show">
												The parenteral anticoagulants may cause uncontrolled and life-threatening bleeding. Protamine,
												the only registered
												heparin antidote, is partially effective against low–molecular weight heparins, completely
												ineffective against
												fondaparinux and may cause unacceptable toxicity. Therefore, we aimed to develop a synthetic
												compound for safe and
												efficient neutralization of all parenteral anticoagulants. We synthesized pegylated PMAPTAC
												block copolymers, and then,
												we selected a lead heparin-binding copolymer (HBC). We assessed the effectiveness of HBC in the
												model of arterial
												thrombosis electrically induced in the carotid artery of rats by measuring thrombus weight,
												bleeding time, activated
												partial thromboplastin time, activated clotting time, and anti-factor Xa activity. The
												intravital tissue distribution,
												the cardiorespiratory, and organ toxicity were monitored. HBC diminished antithrombotic and
												anticoagulant effects of
												unfractionated heparin. Moreover, it stopped bleeding and completely reversed the enhancement of
												clotting times and
												anti-factor Xa activity caused by enoxaparin or fondaparinux. We observed slight pulmonary
												congestion and cell
												infiltration, but the cardiorespiratory parameters remained unchanged. We found a strong signal
												of fluorescently-labeled
												HBC in the urine, and a weaker in the liver and in the kidney. No signs of hepatic or
												nephrotoxicity were observed in
												the blood biochemistry or histopathologic examination. We developed a copolymer efficiently
												neutralizing effects of
												heparins in the living organism, which shows a very promising efficacy/safety profile and may
												help in the management of
												uncontrolled bleeding resulting from an anticoagulant injection. HBC could enable the safe
												replacement of unfractionated
												heparin with low–molecular weight heparins in patients undergoing cardiac surgery and complex
												vascular procedures.
											</p>
											<a type="button" class="btn btn-outline-success" target="_blank" rel="noopener noreferrer"
												href="https://www.translationalres.com/article/S1931-5244(16)30102-5/fulltext">
												Learn more
											</a>
										</div>
									</div>


								</div>
							</div>
						</div>
					</div>
				</div>
			</div>
			</div>
		</section>

		<section id="projects" class="projects bg-dark">

			<div class="container text-center">
				<h2 class="text-light">My projects:</h2>
				<p class="lead text-light ">
					I completed those projects as principal or co-investigator:
				</p>
				<div class="row row-cols-1 row-cols-md-2">
					<div class="col mb-4">
						<div class="card">
							<img src="./img/projects/mnisw.png" style="height: 200px" class="card-img-top" alt="...">
							<div class="card-body">
								<h5 class="card-title">Ministry of Science and Higher Education</h5>
								<h5 class="card-title text-primary">2019 - 2020</h5>
								<h4 class="card-subtitle">Principal Investigator</h4>
								<p class="card-text lead pt-2">Comparison of the effects of HBC, protamine and ciraparantag on the
									cardio-respiratory
									systems functions in preclinical
									safety studies.</p>
							</div>
							<div class="card-footer">
								<!-- <small class="text-muted">Grant value: 1 000 000 PLN</small> -->
								<button class="btn btn-outline-success float-right " data-toggle="modal" data-target="#projectModal"
									data-title="Title" data-desc="Description of the project, will be soon available ...">See
									details</button>
							</div>
						</div>
					</div>
					<div class="col mb-4">
						<div class="card">
							<img src="./img/projects/NCN.jpg" class="card-img-top" style="height: 200px" alt="...">
							<div class="card-body">
								<h5 class="card-title">National Science Centre</h5>
								<h5 class="card-title text-primary">2017 - 2021</h5>
								<h4 class="card-subtitle">Principal Investigator</h4>
								<p class="card-text lead pt-2">The evaluation of protamine-induced thrombocytopenia and its potential
									thromboembolic complications in experimental
									animal models.</p>
							</div>
							<div class="card-footer">
								<!-- <small class="text-muted">Grant value: 1 000 000 PLN</small> -->
								<button class="btn btn-outline-success float-right " data-toggle="modal" data-target="#projectModal"
									data-title="Title" data-desc="Description of the project, will be soon available ...">See
									details</button>
							</div>
						</div>
					</div>
					<div class="col mb-4">
						<div class="card">
							<img src="./img/projects/NCN.jpg" class="card-img-top" style="height: 200px" alt="...">
							<div class="card-body">
								<h5 class="card-title">National Science Centre</h5>
								<h5 class="card-title text-primary">2017 - 2021</h5>
								<h4 class="card-subtitle">Co-Investigator</h4>
								<p class="card-text lead pt-2"">Block polyelectrolytes regulating thrombosis - synthesis, physicochemical analysis,
									and biological studies.</p>
							</div>
							<div class=" card-footer">
									<!-- <small class="text-muted">Grant value: 1 000 000 PLN</small> -->
									<button class="btn btn-outline-success float-right " data-toggle="modal" data-target="#projectModal"
										data-title="Title" data-desc="Description of the project, will be soon available ...">See
										details</button>
							</div>
						</div>
					</div>
					<div class="col mb-4">
						<div class="card">
							<img src="./img/projects/ncbr.jpg" class="card-img-top" style="height: 200px" alt="...">
							<div class="card-body">
								<h5 class="card-title">National Centre for Research and Development</h5>
								<h5 class="card-title text-primary">2017 - 2018</h5>
								<h4 class="card-subtitle">Co-Investigator</h4>
								<p class="card-text lead pt-2"">The use of cationic polymer to stop bleeding induced by unfractionated or
									low-molecular-weight heparins.</p>
							</div>
							<div class=" card-footer">
									<!-- <small class="text-muted">Grant value: 1 000 000 PLN</small> -->
									<button class="btn btn-outline-success float-right " data-toggle="modal" data-target="#projectModal"
										data-title="Title" data-desc="Description of the project, will be soon available ...">See
										details</button>
							</div>
						</div>
					</div>
					<div class="col m-auto mb-4 pb-4">
						<div class="card">
							<img src="./img/projects/NCN.jpg" class="card-img-top" style="height: 200px" alt="...">
							<div class="card-body">
								<h5 class="card-title">National Science Centre</h5>
								<h5 class="card-title text-primary">2013 - 2015</h5>
								<h4 class="card-subtitle">Co-Investigator</h4>
								<p class="card-text lead pt-2"">The development of the new safe and controlled anticoagulant therapy with the use
									of chemically modified compounds in
									the models of experimentally induced arterial and venous thrombosis.</p>
							</div>
							<div class=" card-footer">
									<!-- <small class="text-muted">Grant value: 1 000 000 PLN</small> -->
									<button class="btn btn-outline-success float-right " data-toggle="modal" data-target="#projectModal"
										data-title="Title" data-desc="Description of the project, will be soon available ...">See
										details</button>
							</div>
						</div>
					</div>
				</div>
			</div>


			<!-- modal -->
			<div class="modal fade" id="projectModal" tabindex="-1" aria-labelledby="modal for projects" aria-hidden="true">
				<div class="modal-dialog modal-lg modal-dialog-centered modal-dialog-scrollable" role="document">
					<div class="modal-content">
						<div class="modal-header">
							<h5 class="modal-title" id="projectModalLabel"></h5>
							<button type="button" class="close" data-dismiss="modal" aria-label="Close">
								<span aria-hidden="true">&times;</span>
							</button>
						</div>
						<div class="modal-body">
						</div>
						<div class="modal-footer">
							<button type="button" class="btn btn-secondary" data-dismiss="modal">Close</button>
						</div>
					</div>
				</div>
			</div>


		</section>
		<section id="contact" class="d-flex flex-column justify-content-center align-items-center">
			<form id="form" class="row ddd needs-validation" novalidate
				enctype="text/plain" role="form">
				<h3 class="w-100 text-center mb-3">Contact me:</h3>
				<div class="col-12">
					<div class="form-group row">
						<label class="col-2 text-left text-md-right col-form-label" for="name">Name</label>
						<div class="col-12 col-md-8">
							<div class="input-group">
								<input id="name" name="name" placeholder="Enter your name" type="text" required pattern='.{3,}'
									class="formInput form-control form-control-lg">
								<div class="input-group-append">
									<div class="input-group-text">
										<i class="fa fa-address-book"></i>
									</div>
								</div>
								<div class="invalid-feedback">enter your name</div>
							</div>
						</div>
					</div>
					<div class="form-group row">
						<label for="email" class="col-12 col-sm-2 text-left text-md-right col-form-label">E-mail</label>
						<div class="col-12 col-md-8">
							<div class="input-group">
								<input id="email" required name="email" placeholder="Enter your e-mail address" type="email" value=""
									class="formInput form-control form-control-lg">
								<div class="input-group-append">
									<div class="input-group-text">
										&commat;
									</div>
								</div>
								<div class="invalid-feedback">enter a valid e-mail address</div>
							</div>
						</div>
					</div>
					<div class="form-group row">
						<label for="institution" class="col-12 col-sm-2  col-form-label text-left text-md-right">Institution</label>
						<div class="col-12 col-md-8">
							<div class="input-group">
								<input required id="institution" name="institution" placeholder="Enter where are you from" type="text"
									pattern='.{3,}' class="formInput form-control form-control-lg">
								<div class="input-group-append">
									<div class="input-group-text">
										<i class="fas fa-university"></i>
									</div>
								</div>
								<div class="invalid-feedback">enter your institution</div>
							</div>
						</div>
					</div>
					<div class="form-group row">
						<label for="messageText" class="col-12 col-sm-2  col-form-label text-left text-md-right">Message</label>
						<div class="col-12 col-md-8 ">
							<textarea id="messageText" name="messageText" cols="40" rows="5"
								class="formInput form-control form-control-lg" required aria-describedby="textareaHelpBlock"></textarea>
							<div class="invalid-feedback">please write something</div>
							<small id="textareaHelpBlock" class="form-text text-muted">Enter your message</small>
						</div>
					</div>
					<div class="form-group row">
						<div class="offset-0 offset-md-2 col-8">
							<button id="sssss" name="submit"  class="btn btn-info" value="submitted from joanna.science"
								>Submit</button>
						</div>
					</div>
				</div>
			</form>
		</section>


		<footer class="footer pt-4 bg-dark text-white font-weight-light" id="footer">
			<div class="container-fluid">
				<div class="row text-center justify-content-around align-items-center">
					<div class="col-md-6 col-lg-3 pb-2 order-1 order-lg-0 footer__line"> made with ❤ by Staszek Zajaczkowski<br />
						visit: <a href="http://www.staszek.ovh" target="_blank" rel="noopener noreferrer">staszek.ovh</a>
						<div class="mt-5 text-small font-weight-lighter"> <small>&#169; Stanislaw Zajaczkowski 2020</small><br />
							<small>
								Icons by
								<a href="https://icons8.com/icon/CIdAWzSJTHB3/add-bookmark" target="_blank"
									rel="noopener noreferrer">Icons8</a> &amp; <a href="https://fontawesome.com/" target="_blank"
									rel="noopener noreferrer">fontAwesome</a>
							</small>
						</div>

					</div>
					<div class="col-md-6 col-lg-3 pb-3 footer__line">
						<span>Contact me directly:</span><br />
						e-mail: <a href="mailto:joanna.miklosz@umb.edu.pl">joanna.miklosz@umb.edu.pl</a>
					</div>
					<div class="col-md-6 col-lg-3 pb-2 footer__line">
						<ul class="list-unstyled">
							<li>
								<a href="https://www.researchgate.net/profile/Joanna_Miklosz " target="_blank"
									rel="noopener noreferrer">Research Gate</a>
							</li>
							<li><a href="https://scholar.google.pl/citations?user=xamzqDYAAAAJ&hl=pl" target="_blank"
									rel="noopener noreferrer">Google Scholar</a></li>
							<li><a href="https://www.linkedin.com/in/joanna-mik%C5%82osz-402540162/?originalSubdomain=pl"
									target="_blank" rel="noopener noreferrer">Linked In</a></li>
							<li><a href="https://orcid.org/0000-0003-0958-0454" target="_blank" rel="noopener noreferrer">ORCID</a>
							</li>
							<li><a href="https://www.scopus.com/authid/detail.uri?authorId=57190427945" target="_blank"
									rel="noopener noreferrer">Scopus</a>
							</li>
						</ul>

					</div>
					<div class="col-md-6 col-lg-3 pb-2 footer__line">
						<ul class="list-unstyled">
							<li><u>My current University address:</u></li>
							<li>Department of Pharmacodynamics</li>
							<li>Medical University of Bialystok</li>
							<li>Mickiewicza 2C Str, 15-089 Białystok </li>
							<li>tel./fax: +48 85 748-56-01</li>
							<li>e-mail:<a href="mailto: farmakodynamika@umb.edu.pl"> farmakodynamika@umb.edu.pl</a></li>
						</ul>
					</div>
				</div>
			</div>
		</footer>
	</main>

	<!-- bootstrap scripts -->
	<script src="https://code.jquery.com/jquery-3.5.1.slim.min.js"
		integrity="sha384-DfXdz2htPH0lsSSs5nCTpuj/zy4C+OGpamoFVy38MVBnE+IbbVYUew+OrCXaRkfj"
		crossorigin="anonymous"></script>
	<script src="./bootstrap/bootstrap.bundle.min.js"></script>
	<script src="https://www.gstatic.com/firebasejs/8.2.0/firebase-app.js"></script>
	<script src="https://www.gstatic.com/firebasejs/8.2.0/firebase-firestore.js"></script>
	<script src="https://www.gstatic.com/firebasejs/8.2.0/firebase-analytics.js"></script>
	<script src="./js/main.js"></script>
</body>

</html>